- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05553405
Neuroimmune Mechanisms in Obesity
Aim 1: To measure levels of microglia using the radiotracer [11C]PBR28 and PET brain imaging in obese (n=50) vs. lean individuals (n=50). The investigators will recruit 100 subjects who will participate in a single [11C]PBR28 scan to measure levels of TSPO, a marker of microglia.
Aim 2: To determine differences in brain functional connectivity at rest and in response to a decision- making task in obese (n=50) vs. lean individuals (n=50) using fMRI imaging. The same subjects from Aim 1 will participate in a resting state functional magnetic resonance imaging (fMRI) followed by a decision making task during fMRI acquisition.
Aim 3: To assess whether acute elevation of lipid levels through intralipid infusion in lean, healthy individuals (n=20) will induce microglial activation. 20 lean individuals will be recruited to participate in a paradigm that includes a baseline [11C]PBR28 scan, an infusion of intralipid, and a second [11C]PBR28 scan approximately 4 hours post intralipid infusion. The investigators will attempt to utilize subjects from aim 1 in order to use their baseline scans for this paradigm.
Aim 4: To determine whether there are differences in levels of microglia between individuals with and without type 1 diabetes (n=20). 20 patients with diabetes (type 1 diabetes or type 2 diabetes)will be recruited to participate in a single [11C]PBR28 scan to compare to Aim 1 participants.
Study Overview
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06519
- Yale University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18-55 years
- Able to read and write English and provide voluntary informed consent
- Physically and psychiatrically healthy by medical history, physical, psychiatric, neurological, EKG and laboratory examinations
- For Aims 1-3: HbA1C < 5.7%
- For Aim 4: HbA1C >6.5% and known diagnosis of T1DM or T2DM
Exclusion Criteria:
- Abnormal labs including Creatinine>1.5mg/dL, Hematocrit < 35% for females and < 39% for males, ALT/AST >2.5X upper limit of normal, abnormal TSH
- Known significant thyroid, hepatic, neurologic, psychiatric, cerebrovascular, or cardiovascular disease
- >5% body weight change in last 6 months
- Current or recent regular steroid use in last 6 months, illicit drug use that is deemed to interfere with results including problematic alcohol use as defined by NIAAA
- Current regular use of psychotropic and/or potentially psychoactive prescription medications
- Regular use of any vitamins/supplements that could affect lipids
- Current regular use of non-steroidal anti-inflammatory medications, statins, or lipid lowering agents
- Vaccination in the last month
- Individuals who are classified as "low binders" for the rs6971 polymorphism (<10% of the population)
- For females, physical or laboratory (-HCG) evidence of pregnancy, seeking pregnancy, or lactating. A urine drug screen and pregnancy test will be performed at screening and prior to the imaging session. Subjects who screen positive will be excluded.
Note: If a subject tests positive for an illicit substance, the PI will determine if the substance would interfere with the results and may terminate participation if applicable. Results of the test would only be noted in the subjects de-identified chart to document the occurrence.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Baseline [11C]PBR28 PET Scan
Subjects will complete a 120-minute baseline [11C]PBR28 PET scan.
|
|
Experimental: Post-Intralipid Infusion [11C]PBR28 PET Scan
Subjects will complete a second 120-minute [11C]PBR28 PET scan 4 hours after Intralipid Infusion
|
Intralipid 20% (a 20% IV fat emulsion) is a sterile, non-pyrogenic fat emulsion prepared for IV administration as a source of calories and essential fatty acids.
It is made up of 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin and water for injection.
In addition, sodium hydroxide has been added to adjust the pH so that the final product pH is 8.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline [11C]PBR28 VT values
Time Frame: At baseline
|
[11C]PBR28 VT values in our primary regions of interest (PFC and hippocampus) from PET Scan.
Linear mixed-effect models will be conducted to evaluate differences in [11C]PBR28 VT values between lean, healthy controls (n=40) and individuals with obesity (n=40), controlling for rs6971 genotype, age, and sex.
|
At baseline
|
Post-Intralipid [11C]PBR28 VT values
Time Frame: Approximately 3 Hours After Intralipid Infusion
|
[11C]PBR28 VT values in our primary regions of interest (PFC and hippocampus) from PET Scan.
Linear mixed-effect models will be conducted to evaluate differences in [11C]PBR28 VT values between lean, healthy controls (n=40) and individuals with obesity (n=40), controlling for rs6971 genotype, age, and sex.
|
Approximately 3 Hours After Intralipid Infusion
|
Baseline Functional Connectivity
Time Frame: At baseline
|
ICD values will be obtained from primary a priori regions of interest (vmPFC and hippocampus) with PET Scan.
Independent t-tests will be used to compare the ICD data between the study groups.
|
At baseline
|
Post-Intralipid Functional Connectivity
Time Frame: Approximately 3 Hours After Intralipid Infusion
|
ICD values will be obtained from primary a priori regions of interest (vmPFC and hippocampus) with PET Scan.
Independent t-tests will be used to compare the ICD data between the study groups.
|
Approximately 3 Hours After Intralipid Infusion
|
Baseline Microglial Activation
Time Frame: At baseline
|
Regional [11C]PBR28 VT values from pre-lipid infusion PET Scan
|
At baseline
|
Post-Intralipid Microglial Activation
Time Frame: Approximately 3 Hours After Intralipid Infusion
|
Percent change in regional [11C]PBR28 VT values from pre-lipid infusion PET Scan to post-lipid infusion PET Scan will be calculated across brain regions.
Increased microglial activation will be measured as a 20% or more increase in TSPO levels from scan 1 to scan 2
|
Approximately 3 Hours After Intralipid Infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Baseline Visual Attention
Time Frame: At baseline
|
Visual attention: response latency to identify card color (log10(ms); higher ~ worse attention).
|
At baseline
|
Post-Intralipid Infusion Visual Attention
Time Frame: Approximately 1 Hour After Intralipid Infusion
|
Visual attention: response latency to identify card color (log10(ms); higher ~ worse attention).
|
Approximately 1 Hour After Intralipid Infusion
|
Baseline Visual Learning
Time Frame: At baseline
|
Visual learning: % of correctly identified repeat cards (arcsine(% correct); higher values ~ better learning).
|
At baseline
|
Post-Intralipid Infusion Visual Learning
Time Frame: Approximately 1 Hour After Intralipid Infusion
|
Visual learning: % of correctly identified repeat cards (arcsine(% correct); higher values ~ better learning).
|
Approximately 1 Hour After Intralipid Infusion
|
Baseline Verbal Memory
Time Frame: At baseline
|
Verbal memory: # of correctly recalled items from a grocery list (3 trials).
Verbal recall: # of correctly recalled items from a grocery list after a delay (1 trial; higher ~ better memory/recall).
|
At baseline
|
Post-Intralipid Verbal Memory
Time Frame: Approximately 1 Hour After Intralipid Infusion
|
Verbal memory: # of correctly recalled items from a grocery list (3 trials).
Verbal recall: # of correctly recalled items from a grocery list after a delay (1 trial; higher ~ better memory/recall).
|
Approximately 1 Hour After Intralipid Infusion
|
Baseline Executive Function
Time Frame: At baseline
|
Executive function: number of errors navigating a 'hidden' maze (5 trials; higher ~ worse executive function).
|
At baseline
|
Post-Intralipid Executive Function
Time Frame: Approximately 1 Hour After Intralipid Infusion
|
Executive function: number of errors navigating a 'hidden' maze (5 trials; higher ~ worse executive function).
|
Approximately 1 Hour After Intralipid Infusion
|
Baseline Visual-Motor Processing Speed
Time Frame: At baseline
|
Visual-motor processing speed: response latency to detect a card flipped over (log10(ms); higher ~ worse processing speed).
|
At baseline
|
Post-Intralipid Visual-Motor Processing Speed
Time Frame: Approximately 1 Hour After Intralipid Infusion
|
Visual-motor processing speed: response latency to detect a card flipped over (log10(ms); higher ~ worse processing speed).
|
Approximately 1 Hour After Intralipid Infusion
|
Baseline Working Memory
Time Frame: At baseline
|
Working memory: % of correctly identified cards that matched the card presented either one- or two-cards previously (arcsine(% correct); higher ~ better working memory).
|
At baseline
|
Post-Intralipid Working Memory
Time Frame: Approximately 1 Hour After Intralipid Infusion
|
Working memory: % of correctly identified cards that matched the card presented either one- or two-cards previously (arcsine(% correct); higher ~ better working memory).
|
Approximately 1 Hour After Intralipid Infusion
|
Baseline Social Cognition
Time Frame: At baseline
|
Social cognition: response latency to identify the mismatched facial expression based on its emotional content (ms; log10; higher ~ worse social cognition).
|
At baseline
|
Post-Intralipid Social Cognition
Time Frame: Approximately 1 Hour After Intralipid Infusion
|
Social cognition: response latency to identify the mismatched facial expression based on its emotional content (ms; log10; higher ~ worse social cognition).
|
Approximately 1 Hour After Intralipid Infusion
|
Baseline Reward Responsiveness
Time Frame: At baseline
|
Reward responsiveness will be quantified via computerized Probabilistic Reward Task
|
At baseline
|
Post-Intralipid Reward Responsiveness
Time Frame: Approximately 1 Hour After Intralipid Infusion
|
Reward responsiveness will be quantified via computerized Probabilistic Reward Task
|
Approximately 1 Hour After Intralipid Infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kelly Cosgrove, PhD, Yale University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2000031993
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Intralipid Infusion
-
University of MinnesotaCompleted
-
Beth Israel Deaconess Medical CenterTerminatedHypertriglyceridemiaUnited States
-
Emory UniversityAmerican Diabetes AssociationCompletedDiabetes Mellitus, Type 2United States
-
Cairo UniversityTerminated
-
Indiana UniversityCompletedComparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical NeonatesCholestasis of Parenteral NutritionUnited States
-
Woman's Health University Hospital, EgyptCompleted
-
Cairo UniversityCompleted
-
Ahmed Mohamed Bahaa Eldin AhmedAin Shams Maternity HospitalUnknown
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)Recruiting
-
Ain Shams UniversityRecruiting